S-1/A: Odyssey Therapeutics Files for IPO, Plans Nasdaq Listing

Odyssey Therapeutics, Inc. has filed an amendment to its S-1 registration statement, detailing plans for an initial public offering of 13,240,000 shares of common stock with an estimated price range of $16.00 to $18.00 per share, aiming for a Nasdaq listing under the symbol ODTX.

Summary

• Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune and inflammatory diseases.
• The company has filed an S-1/A amendment with the SEC, indicating its intention to go public.
• Odyssey plans to offer 13,240,000 shares of common stock, with an anticipated initial public offering price between $16.00 and $18.00 per share.
• The company has applied to list its common stock on the Nasdaq Capital Market under the trading symbol ODTX.
• A concurrent private placement is expected to occur, with TPG LSI Rise Orazio II, L.P. purchasing approximately $25.0 million in shares.
• The company has two lead product candidates: OD-001, an oral small-molecule inhibitor of RIPK2 in Phase 2a development for ulcerative colitis, and OD-002, an oral small-molecule inhibitor of SLC15A4 in IND-enabling studies.
• Odyssey reported a net loss of $148.6 million for the year ended December 31, 2025, and had cash, cash equivalents, and marketable securities of $216.6 million as of that date.
• The company expects the proceeds from the offering and private placement, along with existing cash, to fund operations into the second half of 2028.
• The company's management has concluded there is substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the company's significant net losses, going concern doubts, and lack of approved products, despite promising preclinical and early-stage clinical data for its lead candidates.

Positives

• OD-001, the lead product candidate, has achieved proof-of-concept in a Phase 2a trial for ulcerative colitis.
• OD-001 demonstrated good tolerability and provided continuous target coverage in Phase 1 trials.
• OD-001 showed patient benefit across multiple disease-relevant endpoints in the Phase 2a trial, with no serious adverse events or discontinuations due to adverse events.
• The company has a diversified pipeline of wholly owned preclinical programs.
• The management team and board of directors have a strong track record in therapeutic development and company building.
• The company has raised significant capital since its inception, totaling approximately $726.5 million.
• The company expects its existing cash and proceeds from the offering to fund operations into the second half of 2028.

Negatives

• The company has a limited operating history and has incurred substantial net losses since inception.
• Odyssey has no products approved for commercial sale and has never generated revenue from product sales.
• The company expects to continue incurring significant losses for the foreseeable future.
• The company has substantial doubt about its ability to continue as a going concern.
• The company will require substantial additional capital to finance its operations.
• The company's business depends entirely on the success of its product candidates, which face inherent risks of failure.
• The company has recently remediated a material weakness in its internal control over financial reporting.

Risks

• The company is a clinical-stage biotechnology company with a limited operating history and a history of incurring substantial net losses.
• The company has no products approved for commercial sale, has never generated revenue from product sales and may never be profitable.
• Even if this offering and the concurrent private placement are successful, the company will require substantial additional capital to finance its operations.
• The company's business depends entirely on the success of its product candidates and development programs, including OD-001 and OD-002.
• The company has never successfully completed any large-scale or pivotal clinical trials with its product candidates, and may be unable to do so for any product candidates it develops.
• Preclinical and clinical development involves a lengthy and expensive process, with an uncertain outcome.
• The company faces substantial competition, which may result in others discovering, developing or commercializing drugs before or more successfully than the company does.
• If the company is unable to obtain and maintain sufficient intellectual property protection for its product candidates, its ability to successfully develop and commercialize them may be adversely affected.
• The company relies on third parties to conduct its preclinical studies and clinical trials.
• The company relies on third-party manufacturers and suppliers to supply its product candidates.
• The company recently remediated a material weakness in its internal control over financial reporting.
• An active and liquid trading market for the company's common stock may not develop, and investors may not be able to resell their shares at or above the initial public offering price.
• The company's stock price may be volatile, which could result in substantial losses for investors purchasing shares in this offering.
• The company will incur significant increased costs as a result of operating as a public company.
• The company's ability to use its net operating loss carryforwards and certain other tax attributes to offset taxable income or taxes may be limited.
• Recent and future changes to tax laws could materially adversely affect the company.
• The company is an emerging growth company and a smaller reporting company, and its election of reduced reporting requirements may make its common stock less attractive to investors.
• Anti-takeover provisions in the company's organizational documents and under Delaware law could prevent or delay an acquisition that may be beneficial to stockholders.
• The company's reliance on third parties for development activities will reduce its control over these activities.
• The company's future success depends on its ability to manufacture its products, on a timely basis with acceptable manufacturing costs, while at the same time maintaining good quality and complying with applicable regulatory requirements.

Future Outlook

The company expects its existing cash, cash equivalents, and marketable securities, along with the net proceeds from the offering and concurrent private placement, to be sufficient to fund its operations into the second half of 2028. However, substantial additional financing will be necessary to continue research and development activities and operations.

Management Comments

• We believe our deep understanding of immunobiology, coupled with leading expertise in medicinal and computational chemistry, protein biochemistry, structural biology, genetics, and pharmacology, allows us to identify and drug key signaling nodes that drive disease.
• By targeting innate immune responses, our product candidates have the potential, whether as monotherapies or in combination, to address the issue of downstream cytokine redundancy while having less immunosuppressive risk.
• We believe that modulating key signaling nodes in the innate immune system, given its proximal role in initiating immune responses, has the potential to afford more effective and safer immunomodulators that could provide transformative benefit for patients.
• We believe OD-001 has the potential to be the first approved oral therapy for use as a monotherapy or in combination with other advanced therapies in patients with moderate-to-severe disease to potentially break the therapeutic ceiling.

Industry Context

StockSavvy.ai notes that Odyssey Therapeutics is operating in the highly competitive biopharmaceutical sector, focusing on immunology and autoimmune diseases. The company's strategy of targeting innate immune responses and utilizing both small molecules and protein therapeutics aligns with current trends in drug discovery aimed at addressing unmet needs in complex diseases. The company's reliance on experienced management and a strong scientific advisory board, coupled with significant venture capital backing, positions it to navigate the challenging drug development landscape.

Comparison to Industry Standards

• The company's lead candidate, OD-001, is in Phase 2a for ulcerative colitis, a common inflammatory bowel disease. Approved therapies for IBD, while numerous, have modest remission rates (around 20% placebo-adjusted) and a significant portion of patients lose response over time, indicating an unmet need for novel mechanisms.
• The company's approach of targeting RIPK2, a key signaling protein in the innate immune system, is differentiated from current IBD therapies that primarily focus on downstream adaptive immune responses (cytokines, T cells). This upstream targeting aims to address core pathology and potentially overcome resistance to existing treatments.
• The company's OD-002 program targets SLC15A4 for autoimmune diseases like SLE, aiming to improve upon existing therapies such as interferon blockers (e.g., anifrolumab) and TLR7/8 inhibitors, which have shown limitations in efficacy or breadth of action.
• The company's OD-003 program, a TNFR2 agonist for Treg modulation, aims to overcome limitations of IL-2 based therapies, which have shown inconsistent efficacy and potential safety concerns due to lack of selectivity for Treg over other immune cells.
• The company's strategy to advance one or more early-stage programs into clinical development every 12-18 months is ambitious but aligns with efficient pipeline progression common in successful biotech firms.

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings that management believes would have a material adverse effect on its business.

Related Party Transactions

• TPG LSI Rise Orazio II, L.P., an affiliate of an existing stockholder and a director, is expected to purchase approximately $25.0 million in shares in a concurrent private placement.
• Various entities affiliated with SR One Capital Management, OrbiMed Private Investments VIII, L.P., FMR LLC, Jeito II S.L.P., TPG Inc., Lightspeed Venture Partners, and Dimension Capital II, L.P., which include directors or entities with which directors are affiliated, have participated in Series C, C-1, and D preferred stock financings.
• Gary D. Glick, Ph.D., President and CEO, has an executive employment agreement with an initial base salary of $709,000 and a target bonus of 55% of his annual salary, effective upon public listing.
• Jason Haas, CFO, has an executive employment agreement with an initial base salary of $515,000 and a target bonus of 45% of his annual salary, effective upon public listing.
• Collin Todd, SVP Strategy and Business Development, has an executive employment agreement with an initial base salary of $412,000 and a target bonus of 35% of his annual salary, effective upon public listing.
• Ian F. Smith, a director, entered into Restricted Stock Agreements, with certain shares subject to vesting and repurchase rights by the company.

Stakeholder Impact

• Shareholders: Potential dilution from future equity issuances, volatility in stock price, and the impact of anti-takeover provisions on potential acquisition benefits.
• Employees: Potential for retention and motivation through equity awards under new incentive plans, but also subject to the company's financial performance and market conditions.
• Creditors: The company's going concern status and need for future financing may impact its ability to meet financial obligations.
• Suppliers: Reliance on third-party manufacturers and suppliers carries risks of delays or disruptions if these parties fail to meet contractual or regulatory requirements.

Next Steps

• Advance OD-001 to Phase 2b monotherapy trial and Phase 2a combination trial with vedolizumab.
• Advance OD-002 through IND-enabling studies and initiate Phase 1/2a clinical trial.
• Complete IND-enabling activities for OD-003.
• Nominate a bispecific development candidate for the TSLP/IL-33 program.
• Continue lead optimization for the IRAK4 program.
• Execute on existing and pursue additional collaborations, including with Terray Therapeutics.
• Build internal development capabilities to support late-stage development.
• List common stock on the Nasdaq Capital Market under the symbol ODTX upon completion of the offering.

Key Dates

Recommendation

While Odyssey Therapeutics has promising preclinical and early-stage clinical data for its lead candidates OD-001 and OD-002, the company's significant net losses, substantial accumulated deficit, and the conclusion of substantial doubt about its ability to continue as a going concern present considerable risks. The planned IPO and concurrent private placement are crucial for continued operations, but the success of these programs is highly uncertain and dependent on future clinical trial results and regulatory approvals. Given the high-risk, high-reward profile typical of clinical-stage biotechs, a 'hold' recommendation is appropriate, pending further de-risking events such as successful Phase 2b data readouts and regulatory progress.

Keywords

Odyssey Therapeutics, IPO, S-1/A, Biopharmaceutical, Drug Development, Autoimmune Diseases, Inflammatory Diseases, RIPK2 inhibitor, SLC15A4 inhibitor, Ulcerative Colitis, Nasdaq, ODTX, Clinical Trials, Biotech IPO